U.S., Sept. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07842172) titled 'Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms' on Sept. 20.
Brief Summary: This is a multicenter, randomized, open-label, phase III study comparing standard of care use of somatostatin analogues (SSAs) to standard of care observation in patients with neuroendocrine neoplasms following treatment with Peptide Receptor Radionuclide Therapy (PRRT) (ethanol-stabilized Lu-177 dotatate).
Study Start Date: Nov. 30
Study Type: INTERVENTIONAL
Condition:
Neuroendocrine Neoplasm
Gastroenteropancreatic Neuroendocrine Neoplasm
Intervention:
DRUG: Somatost...